Tuesday, July 16, 2024

Forecasted Cancer Tests Market in Japan to Reach $30 Million by 2033

Similar articles

Cancer remains a significant public health concern in Japan, largely attributed to specific dietary habits and high cigarette smoking rates. Against this backdrop, the oncology tests market in Japan is projected to reach $30 million by 2033, according to GlobalData, a leading data and analytics company.

GlobalData’s research reveals that Japan’s oncology tests market is set to account for over 33% of the Asia-Pacific (APAC) market by 2024. This growth underscores the increasing importance and demand for advanced diagnostic and monitoring technologies in the oncology sector. The rising incidence of cancer in Japan necessitates the adoption of innovative diagnostic tools to improve early detection and treatment outcomes.

Nandini Nagpal, Medical Devices Analyst at GlobalData, comments: “For oncology patients, delays in diagnosis and therapeutic follow-up can lead to significant tumor growth, potentially reducing the effectiveness of treatment options. Additionally, issues such as low sensitivity and inadequate diagnostic accuracy make standard screening methods, including imaging tests and endoscopic examinations, less effective. There is an urgent need for more reliable and accurate diagnostic solutions.”

MiRXES Japan Secures JPY20 Million Grant to Develop Non-Invasive Cancer Screening Tests

MiRXES Japan, a fully owned subsidiary of MiRXES, has recently received a grant of up to JPY20 million ($172,000) from the Japan External Trade Organization (JETRO) under their “Subsidy for Projects to Stimulate Direct Investment in Japan” program. This grant will support the establishment of new testing facilities, the transfer of advanced testing technology to Japan, and the evaluation of its effectiveness in the local context.

In collaboration with Nagawa Pharmaceutical Co., MiRXES aims to develop and validate a novel non-invasive oncology biomarker screening test. By introducing MiRXES’ RNA technology to Japanese laboratories, this initiative will enhance access to the company’s flagship products, GastroClear and LungClear, which are designed for the early detection of gastrointestinal and lung cancers respectively.


Japan’s Cancer Control Programs Emphasize Early Detection and Advanced Diagnostics for Improved Outcomes

Nagpal concludes: “Japan has implemented several programs, such as the Basic Plan to Promote Cancer Control Programs, to address the rising cancer incidence. Increasing the number of available screening options will help facilitate early diagnosis, raise screening rates, and ultimately improve cancer survival rates and management in Japan. Expanding access to advanced diagnostic technologies is crucial for better patient outcomes and effective cancer control.”

The report emphasizes the critical role of early detection in oncology treatment, highlighting the need for continuous investment in innovative diagnostic tools. As Japan continues to grapple with high cancer rates, the oncology tests market is poised for significant growth, driven by advancements in technology and increased awareness of the importance of early detection. This trend is expected to not only improve patient outcomes but also reduce the overall burden of cancer on the healthcare system.


You can follow our news on our Telegram and LinkedIn accounts.

Resource: GlobalData, June 24, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article